News
Hepatitis B debrief: Key themes that emerged at AASLD
BOSTON – Hot topics included HBV natural history, novel therapies, and prevention.
News
In recurrent ovarian cancer, secondary surgery does not extend survival
Longer-than-expected survival times and substantial platinum sensitivity among women in the trial could have diluted an independent surgical...
News
Bezafibrate beats placebo in pruritus of chronic cholestasis: The FITCH trial
BOSTON – PPAR agonist now warrants consideration as first-line treatment for “vexing” clinical issue.
News
Nivolumab-ipilimumab combo has ‘robust’ clinical benefit in sorafenib-treated HCC patients
BOSTON – Manageable hepatic adverse events for combination, now under evaluation in a phase 3 trial and accepted for priority review by the FDA....
News
Machine-learning model predicts NASH based on common clinical and lab values
BOSTON – NASHmap could serve as screening tool to reveal more potential undiagnosed patients, according to...
News
Direct-acting antiviral treatment linked to lower mortality in patients with HCC history
BOSTON – Reduced mortality in HCC patients with complete response apparently driven by achievement of sustained...
News
Short-course DAA therapy may prevent hepatitis transmission in transplant patients
BOSTON – While curing infection post transplant works, prevention would be preferable, investigators say.
News
Benefits of BGF triple fixed-dose therapy consistent in COPD patients without exacerbation history
NEW ORLEANS – Findings were similar to overall results of KRONOS, suggesting exacerbation history did not drive...
News
Statins cut long-term CVD risk in kids with familial hypercholesterolemia
There were no cardiovascular-related deaths and one event in treated patients who were followed for 20 years.
News
Tiotropium/olodaterol improved lung function in steroid-free patients with COPD
NEW ORLEANS – Outcomes with the combination therapy compared well with tiotropium monotherapy in patients not receiving inhaled corticosteroids
News
Glecaprevir/pibrentasvir highly effective in HCV genotype 3, among others
BOSTON – Pangenotypic regimen may further progress toward elimination of hepatitis C, investigators say.
News
Terlipressin reversed hepatorenal syndrome in large prospective study
BOSTON – Durable response linked to less need for early renal replacement therapy, investigators say
News
High doses of FXR agonist tropifexor reduce hepatic fat, serum ALT in patients with NASH
BOSTON – Mild pruritus, minor decreases in LDL cholesterol are notable adverse effects of treatment, similar to others in class.
News
Hepatitis C vaccine alters viral trajectory, but fails in chronic infection protection
BOSTON – First-ever randomized study does suggest changes in peak HCV RNA and an HCV RNA change after infection.
News
Duodenal mucosal resurfacing has metabolic effects in type 2 diabetes
BOSTON – Improvements in HbA1c and NASH biomarker favored the procedure over sham procedure in first-ever randomized, double-blind...